Acronym: Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT2 Inhibitors
Purpose: Researchers compared cardiovascular and mortality outcomes associated with SGLT2 inhibitors vs. other glucose-lowering medications in patients with type 2 diabetes
Format: Observational, cohort, retrospective
Treatment Group: SGLT2 inhibitors
Control Group: Other glucose-lowering medications
Number of Participants: 470,128
Inclusion Criteria: Patients with established type 2 diabetes who were new users of SGLT2 inhibitors or other glucose-lowering drugs
- Hospitalization for heart failure
- All-cause death
- Myocardial infarction
- Composite endpoint of all-cause death or hospitalization for heart failure.
Summary: Compared with the other glucose-lowering drugs, SGLT2 inhibitors decreased the risk for all-cause death (HR = 0.51; 95% CI, 0.37-0.7) and hospitalization for heart failure (HR = 0.64; 95% CI, 0.5-0.82). Patients taking SGLT2 inhibitors had lower risk for the composite of all-cause death or heart failure hospitalization vs. those taking other glucose-lowering drugs (HR = 0.6; 95% CI, 0.47-0.76). The risk for myocardial infarction decreased in patients taking SGLT2 inhibitors vs. those taking other glucose-lowering drugs (HR = 0.81; 95% CI, 0.74-0.88). This was also seen with the risk for stroke (HR = 0.68; 95% CI, 0.55-0.84).
Kosiborod M, et al. J Am Coll Cardiol. 2018;doi:10.1016/j.jacc.2018.03.009.
Link to Cardiology Today Article: